Showing results (11-20 of 30) with videos related to
Sort By:
Pageof 3
Frontiers in Pharmacology|May 31, 2019
Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR ModulatorsGert de Wilde, Maarten Gees, Sara Musch, et al.Journal of Medicinal Chemistry|March 23, 2011
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.Journal of Medicinal Chemistry|May 3, 2021
Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary FibrosisOscar Mammoliti, Adeline Palisse, Caroline Joannesse, et al.Science Translational Medicine|February 15, 2023
IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseasesStéphanie Lavazais, Manja Jargosch, Sonia Dupont, et al.Journal of Medicinal Chemistry|March 15, 2021
Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of OsteoarthritisFranck Brebion, Romain Gosmini, Pierre Deprez, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 6, 2013
Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseasesLuc Van Rompaey, René Galien, Ellen M van der Aar, et al.Journal of Medicinal Chemistry|November 5, 2014
Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634Christel J Menet, Stephen R Fletcher, Guy Van Lommen, et al.Journal of Medicinal Chemistry|November 22, 2011
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitorsMarion Flipo, Matthieu Desroses, Nathalie Lecat-Guillet, et al.Cell|June 21, 2014
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathwaysEstelle Marion, Ok-Ryul Song, Thierry Christophe, et al.Journal of Medicinal Chemistry|November 18, 2017
Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High ExtentSteven E Van der Plas, Hans Kelgtermans, Tom De Munck, et al.Pageof 3